Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib + Capecitabine in Elderly NSCLC
NCT00816868Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2009
- Primary completion
- May 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, capecitabine in lung adenocarcinoma (LUAD), sponsored by Sun Yat-sen University. Started Jan 2009; status: completed.
02
Drugs
erlotinibcapecitabine
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT00816868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00816868.